earnings
confidence high
sentiment neutral
materiality 0.70
BMY Q3 revenue $11.2B (-3% YoY), GAAP EPS $0.75, Non-GAAP $1.99
BRISTOL MYERS SQUIBB CO
2022-Q3 EPS reported
$2.00
revenue$34,753,000,000
- Revenue $11.2B, down 3% vs Q3 2021; U.S. revenue up 9% to $7.9B, international down 24% to $3.3B.
- GAAP EPS $0.75, Non-GAAP EPS $1.99; non-GAAP excludes amortization and acquired IPRD charges.
- In-line and new product portfolio grew 8% to $8.6B (13% ex-FX); Revlimid fell 28% to $2.4B.
- Completed Turning Point acquisition; FDA approved Sotyktu for plaque psoriasis in September.
- Adjusted 2022 GAAP EPS guidance; reaffirmed non-GAAP EPS guidance.